Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diovan Clears FDA For Post-Myocardial Infarction Mortality Reduction

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency also removes restriction in labeling limiting heart failure indication to patients intolerant of ACE inhibitors.

You may also be interested in...



Novartis’ Diovan Gets Pediatric Hypertension Nod

Novartis’ top seller will compete with Merck’s Cozaar in the growing pediatric high blood pressure market.

Novartis’ Diovan Gets Pediatric Hypertension Nod

Novartis’ top seller will compete with Merck’s Cozaar in the growing pediatric high blood pressure market.

Novartis Anticipates Diovan Pricing Will Contribute To Near-Term Growth

Pending oral iron-chelating agent Exjade could be priced at a premium compared with current first-line therapy, Novartis says during its third quarter call Oct. 18.

Related Content

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel